04 — Loss of proteostasis
Primary hallmark ("damage") according to López-Otín et al., Cell 2023 (doi:10.1016/j.cell.2022.11.001).
1. Definition
Age-related decline of the network that ensures the cell's proteins are made, folded into the right shape, repaired and destroyed when damaged. Result: accumulation of misfolded proteins and toxic aggregates. Aggregation diseases (Alzheimer's, Parkinson's, ALS, amyloidoses) are its most visible manifestation (Hipp 2019, doi:10.1038/s41580-019-0101-y; Labbadia & Morimoto 2015, doi:10.1146/annurev-biochem-060614-033955).
In plain terms: proteins are the cell's "machines". To work, they must fold like a precise origami. "Assistants" (chaperones) help with folding, "shredders" (proteasome, lysosome) recycle the failed pieces. With age, assistants and shredders run out of steam: the failed origamis pile up and form clumps that clog the cell.
2. Mechanisms and sources
The proteostasis network comprises about 2,000 proteins organised in three branches (Hipp 2019):
- Synthesis and folding: ribosomes and chaperones (heat shock proteins, HSP70, HSP90, chaperonins). Their induction under stress depends on the factor HSF-1, whose response weakens with age.
- Specialised stress responses: the unfolded protein response of the endoplasmic reticulum (UPR-ER) and of mitochondria (UPR-mt), and the integrated stress response (ISR), which slows protein production when the cell is overwhelmed. With age, these responses become less effective or remain stuck in the "brake" position.
- Degradation: the proteasome (ubiquitin-proteasome system, which destroys proteins one by one) and the lysosome through autophagy. Macroautophagy is now a separate hallmark (see file 05); chaperone-mediated autophagy (CMA), which brings proteins one at a time into the lysosome through the LAMP2A receptor, declines with age (Kaushik & Cuervo 2018, doi:10.1038/s41580-018-0001-6).
What happens with age
- Widespread aggregation: in the worm C. elegans, hundreds of proteins become insoluble with age, even in the absence of disease (David 2010, doi:10.1371/journal.pbio.1000450); the proteome becomes imbalanced (Walther 2015, doi:10.1016/j.cell.2015.03.032).
- Sources of damage: oxidation, glycation, carbonylation, translation errors, somatic mutations (file 01), lower energy (ATP needed by chaperones and the proteasome).
- Prion-like spread: some aggregates (amyloid-β, tau, α-synuclein) act as "seeds" that convert healthy proteins and spread from cell to cell, which explains the progression of neurodegenerative diseases through the brain (Jucker & Walker 2013, doi:10.1038/nature12481).
- Causality in animals: boosting HSF-1 extends the worm's life; reducing it shortens it (Hsu 2003, doi:10.1126/science.1083701). Restoring CMA (LAMP2A) in the liver of old mice reduces the accumulation of damaged proteins and improves liver function (Zhang & Cuervo 2008, doi:10.1038/nm.1851).
3. Symptoms and clinical manifestations
Human evidence comes mainly from misfolding diseases ("proteinopathies", more than 50 diseases; Chiti & Dobson 2017, doi:10.1146/annurev-biochem-061516-045115), whose risk soars with age:
| Disease | Aggregating protein | Link with age |
|---|---|---|
| Alzheimer's disease | Amyloid-β, tau | Risk roughly doubling every 5 years after 65 |
| Parkinson's disease | α-synuclein | Age = main risk factor |
| ALS (Charcot disease) | TDP-43, SOD1, FUS | Peak after 60 |
| Huntington's disease | Huntingtin (polyglutamine expansion) | Genetic; onset in adulthood |
| Transthyretin amyloidosis (ATTR) | Transthyretin (TTR) | "Wild-type" form common beyond 75, a cause of heart failure |
| Cataract | Lens crystallins | Almost universal with age |
Genetic forms: mutations that make a protein more unstable (e.g. APP, PSEN1 for Alzheimer's; TTR for hereditary amyloidosis) bring forward the age of disease, which shows that aggregation is causal for these diseases (Chiti & Dobson 2017).
Lysosomal diseases: Niemann-Pick disease type C (accumulation of lipids in lysosomes) illustrates the link between chaperones and lysosomes (Kirkegaard 2010, doi:10.1038/nature08710).
4. Interactions with the other hallmarks
| Hallmark (2023 numbering) | Link with loss of proteostasis |
|---|---|
| 1. Genomic instability | Mutations and errors → defective proteins; repair proteins depend on chaperones. |
| 2. Telomere attrition | Mostly indirect link, through senescence. |
| 3. Epigenetic alterations | Chromatin regulates the expression of chaperones and HSF-1. |
| 5. Disabled macroautophagy | Main route for clearing large aggregates; the two hallmarks reinforce each other (file 05). |
| 6. Deregulated nutrient sensing | mTOR drives protein production; inhibiting it reduces the load and activates autophagy. The insulin/IGF-1 pathway acts through DAF-16 and HSF-1 in the worm (Hsu 2003). |
| 7. Mitochondrial dysfunction | Less ATP for chaperones and the proteasome; misfolded mitochondrial proteins → UPR-mt; aggregates that damage mitochondria. |
| 8. Cellular senescence | Aggregates and reticulum stress can trigger senescence. |
| 9. Stem cell exhaustion | Stem cells maintain enhanced proteostasis; its loss reduces their regenerative capacity. |
| 10. Altered intercellular communication | Spread of aggregates from cell to cell (Jucker & Walker 2013); stress signals transmitted between tissues in the worm. |
| 11. Chronic inflammation | Aggregates activate microglia and the NLRP3 inflammasome. |
| 12. Dysbiosis | In animals: the bacterial amyloid curli accelerates α-synuclein aggregation (old rats; Chen 2016, doi:10.1038/srep34477); the microbiota worsens motor deficits in a mouse model of Parkinson's (Sampson 2016, doi:10.1016/j.cell.2016.11.018); pathological α-synuclein injected into the gut reaches the brain through the vagus nerve (Kim 2019, doi:10.1016/j.neuron.2019.05.035). The hypothesis that Parkinson's starts in the gut is not demonstrated in humans. |
5. Existing or investigational remedies
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Tafamidis | Stabilises TTR (prevents its dissociation) | Approved (cardiac ATTR) | Phase 3 trial: lower all-cause mortality and fewer cardiovascular hospitalisations | Maurer 2018, doi:10.1056/NEJMoa1805689 |
| Patisiran (interfering RNA) | Reduces TTR production | Approved (hereditary ATTR, neuropathy) | Phase 3: improvement of neuropathy and quality of life vs placebo | Adams 2018, doi:10.1056/NEJMoa1716153 |
| NTLA-2001 (in vivo CRISPR-Cas9 editing) | Inactivates the TTR gene in the liver | Human phase 1 trial | A single infusion: mean TTR reduction of ~87 % at the 0.3 mg/kg dose | Gillmore 2021, doi:10.1056/NEJMoa2107454 |
| Lecanemab (antibody) | Clears amyloid-β protofibrils | Approved (early Alzheimer's) | Phase 3: clinical decline slowed by 27 % over 18 months; side effects (brain oedema and microbleeds, ARIA) | van Dyck 2023, doi:10.1056/NEJMoa2212948 |
| Donanemab (antibody) | Amyloid plaques | Approved (early Alzheimer's) | Phase 3: decline slowed by about a third in patients with low/intermediate tau load; ARIA | Sims 2023, doi:10.1001/jama.2023.13239 |
| Arimoclomol | Amplifies the chaperone response (HSP70) | Approved by the FDA on 20 September 2024 (Miplyffa, with miglustat, Niemann-Pick C) (FDA press release) | Phase 2/3: slower progression vs placebo | Mengel 2021, doi:10.1002/jimd.12428; mechanism: Kirkegaard 2010 |
| Sodium phenylbutyrate + taurursodiol (AMX0035) | Reticulum and mitochondrial stress | Positive phase 2; negative phase 3 (PHOENIX), withdrawn from the market in 2024 | Phase 2: slower functional decline in ALS; not confirmed afterwards | Paganoni 2020, doi:10.1056/NEJMoa1916945; withdrawal announced on 4 April 2024 after the failure of PHOENIX (Amylyx press release; Federal Register 2025) |
| ISRIB | Releases the brake of the integrated stress response | Preclinical (mice) | Improves memory (Sidrauski 2013); reverses age-related memory decline in old mice (Krukowski 2020) | doi:10.7554/eLife.00498; doi:10.7554/eLife.62048 |
| Restoring CMA (LAMP2A) | Chaperone-mediated autophagy | Preclinical (transgenic mice) | Better liver function in old mice | Zhang & Cuervo 2008 |
| Rapamycin, caloric restriction | mTOR → less synthesis, more autophagy | Solid preclinical; human trials (see file 05) | Indirect effects on proteostasis | Hipp 2019 |
Finding: real clinical successes concern diseases targeting a single protein (TTR, amyloid-β), with clear benefits for ATTR but modest ones for Alzheimer's. No intervention strengthens the proteostasis network as a whole in humans.
6. Open questions
- Aggregates: cause or defence? Large aggregates could be a way of "storing away" more toxic forms (oligomers). Clearing plaques brings only a modest benefit in Alzheimer's.
- Global vs targeted intervention: can HSF-1, the proteasome or CMA be boosted in humans without risk (cancers also use these networks to survive)?
- Biomarkers: how to measure proteostasis in a living person, outside specific imaging (amyloid PET) or blood markers (p-tau)?
- Translation from the worm: most causal evidence on longevity comes from C. elegans (David 2010; Walther 2015; Hsu 2003).
- Timing of intervention: anti-amyloid trials suggest acting early, before symptoms.
7. References
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
- Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 2019. doi:10.1038/s41580-019-0101-y
- Labbadia J, Morimoto RI. The biology of proteostasis in aging and disease. Annu Rev Biochem 2015. doi:10.1146/annurev-biochem-060614-033955
- Kaushik S, Cuervo AM. Proteostasis and aging. Nat Med 2015. doi:10.1038/nm.4001
- Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol 2018. doi:10.1038/s41580-018-0001-6
- David DC, et al. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol 2010. doi:10.1371/journal.pbio.1000450
- Walther DM, et al. Widespread proteome remodeling and aggregation in aging C. elegans. Cell 2015. doi:10.1016/j.cell.2015.03.032
- Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013. doi:10.1038/nature12481
- Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 2003. doi:10.1126/science.1083701
- Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 2008. doi:10.1038/nm.1851
- Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 2017. doi:10.1146/annurev-biochem-061516-045115
- Kirkegaard T, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010. doi:10.1038/nature08710
- Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. NEJM 2018. doi:10.1056/NEJMoa1805689
- Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. NEJM 2018. doi:10.1056/NEJMoa1716153
- Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. NEJM 2021. doi:10.1056/NEJMoa2107454
- van Dyck CH, et al. Lecanemab in early Alzheimer's disease. NEJM 2023. doi:10.1056/NEJMoa2212948
- Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023. doi:10.1001/jama.2023.13239
- Mengel E, et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial. J Inherit Metab Dis 2021. doi:10.1002/jimd.12428
- Paganoni S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. NEJM 2020. doi:10.1056/NEJMoa1916945
- Sidrauski C, et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife 2013. doi:10.7554/eLife.00498
- Krukowski K, et al. Small molecule cognitive enhancer reverses age-related memory decline in mice. eLife 2020. doi:10.7554/eLife.62048
- Chen SG, et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci Rep 2016. doi:10.1038/srep34477
- Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016. doi:10.1016/j.cell.2016.11.018
- Kim S, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson's disease. Neuron 2019. doi:10.1016/j.neuron.2019.05.035
- FDA. FDA approves first treatment for Niemann-Pick disease, type C (2024). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c
- Amylyx Pharmaceuticals. Formal intention to remove RELYVRIO/ALBRIOZA from the market (4 avril 2024). https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy
DOIs verified via the Crossref API on 2026-10-19.